Genetically determined differences in drug metabolism as a risk factor in drug toxicity
- 31 December 1992
- journal article
- review article
- Published by Elsevier in Toxicology Letters
- Vol. 64-65, 115-122
- https://doi.org/10.1016/0378-4274(92)90180-r
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Human ArylamineN-Acetyltransferase Genes: Isolation, Chromosomal Localization, and Functional ExpressionDNA and Cell Biology, 1990
- Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver.Journal of Clinical Investigation, 1990
- Characterization of the common genetic defect in humans deficient in debrisoquine metabolismNature, 1988
- Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and assignment of the CYP2D locus to chromosome 22Genomics, 1988
- Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of metoprolol, propafenone, diltiazem, and sparteineJournal of Molecular Medicine, 1987
- Die Häufigkeit hepatotoxischer Nebenwirkungen der tuberkulostatischen Kombinationstherapie (INH, RMP, EMB) in Abhängigkeit vom AcetyliererphänotypJournal of Molecular Medicine, 1982
- Impaired oxidation of debrisoquine in patients with perhexiline neuropathy.BMJ, 1982
- Effect of Acetylator Phenotype on the Rate at Which Procainamide Induces Antinuclear Antibodies and the Lupus SyndromeNew England Journal of Medicine, 1978
- POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MANThe Lancet, 1977
- Genetic Control of Isoniazid Metabolism in ManBMJ, 1960